Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S471000
Reexamination Certificate
active
07132441
ABSTRACT:
This invention is in the field of a combination comprising a therapeutically-effective amount of a cyclooxygenase-2 inhibitor, a 5-lipoxygenase inhibitor and an immunosuppressive drug selected from antiproliferative agents, antiinflammatory-acting compounds and inhibitors of leukocyte activation. This combination may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.
REFERENCES:
patent: 4686231 (1987-08-01), Bender et al.
patent: 4889935 (1989-12-01), Musser
patent: 5272178 (1993-12-01), Mueller et al.
patent: 5403857 (1995-04-01), Edwards et al.
patent: 5859257 (1999-01-01), Talley
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 5990148 (1999-11-01), Isakson et al.
patent: 6013644 (2000-01-01), Mills et al.
patent: 6136839 (2000-10-01), Isakson
patent: 6407140 (2002-06-01), Gregory
patent: 6500844 (2002-12-01), Finke et al.
patent: WO 96/38418 (1996-12-01), None
patent: WO 96/38442 (1996-12-01), None
patent: WO 96/41626 (1996-12-01), None
patent: WO 97/29776 (1997-08-01), None
Engelhardt, CA 125:292089, abstract of Br J Rheumatol, 1996, 35 (Suppl 1), 4-12.
Print out of Registry No. 79217-60-0 and 59865-13-3, 2003.□□.
Fung-Leung, CA 123:306186, 1995.
Potier et al., “Comparative Study of Cyclosporin A, Cyclosporin G, and the novel Cyclosporin Derivatives IMM 125 in Isolated Glomeruli and Cultured Rat Mesangial Cells: a Morphometric Analysis.” Nephrol Dial Transplant, 1998, pp. 1406-1411, vol. 13.
Carter et al., 5-Lipoxygenase Inhibitory Activity of Zileuton1,J. Pharm. and Exp. Ther., 1991, pp. 929-937, vol. 256, No. 3, American Society for Pharmacology and Experimental Therapeutics, 1991.
Chang et al., Prevention of ocular inflammation by matrine, prednisolone, and cyclooxygenase and lipoxygenase inhibitors,Acta Pharmacologica Sinica, Mar. 1991, pp. 121-125, vol. 12, No. 2.
Rubin et al., Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenae,Prog. in Inflam. Res. and Therapy, 1991, pp. 103-116.
Tennant et al., Effects of a 5-lipoxygenase inhibitor, REV-5901, on leukotriene and histamine release from human lung tissue in-vitro,J. Pharmacy and Pharmacology, Apr. 1987, pp. 309-311, vol. 39, No. 4.
Anderson Gary
Gregory Susan A.
Isakson Peter C.
G.D. Searle & Co.
Polster, II Philip B.
Seaman D. Margaret
LandOfFree
Immunosuppressive effects of administration of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunosuppressive effects of administration of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunosuppressive effects of administration of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3704630